SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
NCT02013375
Terminated
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease. However, due to a lack of suitable donors, many patients cannot benefit from this strategy. Alternative donor sources are desperately needed to fill this gap. Nearly all patients will have a haploidentical family member who would be able to donate. The use of post transplantation cyclophosphamide has greatly improved the outcome of haploidentical st... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
08/22/2019
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Sickle Cell Disease
Register for Updates
Stem Cell Transplantation for Fanconi Anemia
NCT00167206
Terminated
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.
Gender:
ALL
Ages:
Between 1 day and 18 years
Trial Updated:
08/21/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
NCT00866749
Completed
Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). B. Secondary objective: 1. To evaluate the prognostic significance of minimal residual disease in bone marrow samples at the end of induction and at the end of consolidation in this group of patients. 2. To prospectively evaluate gene hyperm... Read More
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
08/21/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
NCT01454596
Completed
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient's white... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/16/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
Register for Updates
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT00770224
Completed
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2019
Locations: Providence Cancer Center at Providence Hospital, Mobile, Alabama +113 locations
Conditions: Lymphoma
Register for Updates
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
NCT01253460
Terminated
The goal of this clinical research study is to learn if sapacitabine given in combination with 2 standard drugs (cyclophosphamide and rituximab) can help to control CLL and SLL. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
NCT00656123
Completed
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/12/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Colorectal Cancer, Metastatic Cancer
Register for Updates
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
NCT01014767
Terminated
This is a "tissue banking and data review" research study that also has a "clinical" research part: * The goal of the tissue banking part of this study is to store tissue in a research tissue bank by the International Society for Pediatric Oncology (SIOP) at an international reference center for choroid plexus tumors. The tissue will be used in future research related to cancer. * The goal of the data review part of this study is to collect information from the medical records of patients with... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2019
Locations: Tufts Medical Center, Boston, Massachusetts +4 locations
Conditions: Brain Cancer, Choroid Plexus Tumors
Register for Updates
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
NCT00550992
Unknown
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, me... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
07/29/2019
Locations: Children's Hospital Boston, Boston, Massachusetts +12 locations
Conditions: Leukemia
Register for Updates
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
NCT00066469
Completed
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining cyclophosphamide and either prednisone or methylprednisolone with rituximab may be effective in treating lymphoproliferative disease following organ... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/25/2019
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +77 locations
Conditions: Lymphoproliferative Disorder
Register for Updates
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
NCT00027846
Completed
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to determine the effectiveness of specialized radiation therapy either alone or after chemotherapy a... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/24/2019
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +164 locations
Conditions: Brain Tumor, Central Nervous System Tumor
Register for Updates
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
NCT00382109
Completed
This randomized phase III trial is studying tacrolimus, methotrexate, and sirolimus to see how well they work compared to tacrolimus and methotrexate in preventing graft-versus-host disease in young patients who are undergoing donor stem cell transplant for intermediate-risk or high-risk acute lymphoblastic leukemia in second complete remission and high risk acute lymphoblastic leukemia in first remission. Giving chemotherapy, such as thiotepa and cyclophosphamide, and total-body irradiation bef... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/24/2019
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +49 locations
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Register for Updates